The calamitous demise of Vioxx and Celebrex has reinforced the terrific challenges facing companies that hope to develop novel therapies for pain. PainCeptor Pharma Corp. hopes to bring relief for many of the industry's miseries and tackle currently untreated PNS-based pain syndromes by recalibrating the pain management equation to focus on its first term.
7150, Albert-Einstein, Suite 100
St-Laurent, Quebec
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.
Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.
Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.
